UK markets open in 4 hours 16 minutes
  • NIKKEI 225

    27,902.11
    +81.71 (+0.29%)
     
  • HANG SENG

    19,318.93
    -199.36 (-1.02%)
     
  • CRUDE OIL

    77.57
    +0.64 (+0.83%)
     
  • GOLD FUTURES

    1,786.60
    +5.30 (+0.30%)
     
  • DOW

    33,947.10
    -482.78 (-1.40%)
     
  • BTC-GBP

    13,973.79
    -207.62 (-1.46%)
     
  • CMC Crypto 200

    403.01
    -8.21 (-2.00%)
     
  • ^IXIC

    11,239.94
    -221.56 (-1.93%)
     
  • ^FTAS

    4,143.21
    +4.40 (+0.11%)
     

Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk A/S
Novo Nordisk A/S

Bagsværd, Denmark, 15 November 2022 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.

Please find below a statement of such trading in shares issued by Novo Nordisk.

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name of the Board member/Executive/Associated Person

Andreas Fibig

2

Reason for the notification

a)

Position/status

Member of the Board of Directors

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer

a)

Name

Novo Nordisk A/S

b)

LEI

549300DAQ1CVT6CXN342

4

Details of the transaction(s)

a)

Description of the financial instrument,

type of instrument,

ADRs

 

Identification code

NVO

b)

Nature of the transaction

Purchase of ADRs

c)







Price(s) and volume(s)







 

 

 

 

 

Price(s)

Volume(s)

 

 

DKK 800.39

180 ADRs

 

 

DKK 800.75

0.31 ADRs

 

 

 

 

 

d)

Aggregated information

  • Aggregated volume

  • Price



180.31 ADRs

DKK 800.39

e)

Date of the transaction

2022-11-11

f)

Place of the transaction

Nasdaq New York Stock Exchange

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 50,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and YouTube.

Contact for further information

Media:

 

Ambre Brown Morley
+45 3079 9289
abmo@novonordisk.com

Natalia Salomao Abrahao (US)
+1 848 304 1027
niaa@novonordisk.com

Investors:

 

Daniel Muusmann Bohsen
+45 3075 2175
dabo@novonordisk.com

Jacob Martin Wiborg Rode
+45 3075 5956
jrde@novonordisk.com

David Heiberg Landsted
+45 3077 6915
dhel@novonordisk.com

Mark Joseph Root (US)
+1 848 213 3219
mjhr@novonordisk.com

Company announcement No 85 / 2022

Attachment